- Accession Number
A group of oral anti-diabetic drugs designed to treat patients with type 2 diabetes. Thiazolidenediones are compounds that act as agonists of the peroxisome proliferator-activated receptor-gamma increasing tissues sensibility (muscle, adiposity tissue, and liver) to insulin action.
- ATC Classification
Drug Drug Description Rosiglitazone A thiazolidinedione indicated as an adjunct to diet and exercise to maintain glycemic control in type 2 diabetes. Pioglitazone A thiazolidinedione used adjunctively with diet and exercise to normalize glycemic levels in adults with type 2 diabetes mellitus. Ciglitazone Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in... Lobeglitazone Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use... Rivoglitazone Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co. Netoglitazone Netoglitazone (MCC-555) is a hypoglycemic agent. Balaglitazone Balaglitazone has been used in trials studying the treatment of Diabetes Mellitus, Type 2. Troglitazone For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
- Drugs & Drug Targets